Literature DB >> 14688025

Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas.

Karin Fransén1, Maria Klintenäs, Anna Osterström, Jan Dimberg, Hans-Jürg Monstein, Peter Söderkvist.   

Abstract

Colorectal cancer is a multi-step process characterized by a sequence of genetic alterations in cell growth regulatory genes, such as the adenomatous polyposis coli, KRAS, p53 and DCC genes. In the present study mutation analysis was performed with SSCA/direct sequencing of the hot-spot regions in exons 11 and 15 for the BRAF gene and exons 1-2 for the KRAS gene in 130 primary colorectal cancer tumors and correlated with clinico-pathological and mutational data. We also performed mutation analysis of the corresponding conserved regions in the ARAF and RAF-1 genes. Mutations in the BRAF and KRAS genes were found in 11.5 and 40% of the tumors, respectively. One germline exonic and nine germline intronic genetic variants were found in the ARAF and RAF-1 genes. All of the BRAF mutations were located in the kinase domain of the conserved region 3 in exon 15 of the BRAF gene. One novel somatic mutation was also identified in the BRAF gene. The majority of the BRAF mutations were found in colon compared with rectal tumors (P = 0.014). In agreement with others, a statistically significant correlation between BRAF mutations and microsatellite instability could be found. A negative correlation was also evident between mutations in the BRAF and KRAS genes, which supports earlier studies where somatic mutations in these genes are mutually exclusive. Collectively, our results provide support for the idea that activation of the MAP kinase pathway, especially via BRAF and KRAS mutations, is of critical importance for the development of colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14688025     DOI: 10.1093/carcin/bgh049

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  105 in total

Review 1.  Biomarkers in colorectal cancer.

Authors:  B Markman; V Rodríguez-Freixinos; J Tabernero
Journal:  Clin Transl Oncol       Date:  2010-04       Impact factor: 3.405

Review 2.  BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies.

Authors:  Callisia N Clarke; E Scott Kopetz
Journal:  J Gastrointest Oncol       Date:  2015-12

Review 3.  Adjuvant chemotherapy for rectal cancer: Is it needed?

Authors:  Kristijonas Milinis; Michael Thornton; Amir Montazeri; Paul S Rooney
Journal:  World J Clin Oncol       Date:  2015-12-10

Review 4.  New trends in molecular and cellular biomarker discovery for colorectal cancer.

Authors:  Parisa Aghagolzadeh; Ramin Radpour
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

5.  The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers.

Authors:  Rob Glynne-Jones; Maher Hadaki; Mark Harrison
Journal:  J Gastrointest Oncol       Date:  2013-09

6.  TRAF6 promoted the metastasis of esophageal squamous cell carcinoma.

Authors:  Qingqi Han; Feng Yao; Chenxi Zhong; Heng Zhao
Journal:  Tumour Biol       Date:  2013-09-13

7.  Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

Authors:  James A McCubrey; Linda S Steelman; Richard A Franklin; Steven L Abrams; William H Chappell; Ellis W T Wong; Brian D Lehmann; David M Terrian; Jorg Basecke; Franca Stivala; Massimo Libra; Camilla Evangelisti; Alberto M Martelli
Journal:  Adv Enzyme Regul       Date:  2007-03-26

8.  Mutation in BRAF and SMAD4 associated with resistance to neoadjuvant chemoradiation therapy in locally advanced rectal cancer.

Authors:  Dan Jiang; Xin Wang; Yajian Wang; Dana Philips; Wenjian Meng; Moli Xiong; Junyi Zhao; Linyong Sun; Du He; Kun Li
Journal:  Virchows Arch       Date:  2019-05-06       Impact factor: 4.064

9.  Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma.

Authors:  Diego F Calvisi; Sara Ladu; Alexis Gorden; Miriam Farina; Ju-Seog Lee; Elizabeth A Conner; Insa Schroeder; Valentina M Factor; Snorri S Thorgeirsson
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

10.  Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer.

Authors:  Mariella Dono; Carlotta Massucco; Silvana Chiara; Claudia Sonaglio; Marco Mora; Anna Truini; Giannamaria Cerruti; Gabriele Zoppoli; Alberto Ballestrero; Mauro Truini; Manlio Ferrarini; Simona Zupo
Journal:  Mol Med       Date:  2013-02-08       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.